SELLAS Life Sciences Group, Inc. SLS
NASDAQ · United States · Health Technology
$11.41-0.90 (-7.31%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
SLS investors have been closely watching for two key developments: late-stage REGAL study data for the company’s GPS cancer vaccine in acute myeloid leukemia and a decision on whether SLS009 will advance into human trials for pancreatic cancer.
SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.